[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585540":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":38,"collaborators":26,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":26,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"Mansoura University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pentoxifylline Arm","EXPERIMENTAL","Participants in this arm will receive Pentoxifylline 400 mg twice daily orally with food, in addition to their conventional medications for chronic kidney disease (CKD). Pentoxifylline treatment will be administered for 6 months, concurrent with the study duration. Conventional medications will continue as prescribed by their treating physician and will be consistent with standard of care for CKD.",[13],"Drug: Pentoxifylline 400 MG Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional Medication Group","ACTIVE_COMPARATOR","Participants in this arm will receive conventional medications for chronic kidney disease (CKD) only. They will not receive Pentoxifylline. Conventional medications will be administered as prescribed by their treating physician and will be consistent with standard of care for CKD. This arm serves as the control group to compare against the Pentoxifylline arm in evaluating the potential effect of Pentoxifylline on vascular calcification.",[19],"Other: Conventional Medications for Chronic Kidney Disease",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Pentoxifylline 400 MG Oral Tablet","Oral tablet, 400 mg, administered twice daily with food for 6 months. To be taken in addition to conventional medications for chronic kidney disease.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Conventional Medications for Chronic Kidney Disease","This arm receives conventional medical management for chronic kidney disease (CKD). This includes medications and treatments as deemed necessary and appropriate by the participant's treating physician, according to established clinical guidelines for CKD. These may include, but are not limited to, medications for blood pressure control, management of diabetes, anemia treatment, mineral and bone disorder management, and fluid and electrolyte balance management. The specific medications and treatments are individualized and not dictated by the study protocol, but follow standard clinical practice for CKD.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Dina M Gaber, M.B.B. Ch","CONTACT","+201010402101","+201062376458","dinamasud11@gmail.com",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dina Massoud Gaber","Resident in Nephrology","100585540","phase-1-pentoxifylline-for-vascular-calcification-in-kidney-disease-100585540",false,"NCT06903689","Pentoxifylline for Vascular Calcification in Kidney Disease","Exploring the Potential Effect of Pentoxifylline in Mitigating Vascular Calcification in Chronic Kidney Disease Patients","PTX-CALC-CKD","Inclusion Criteria:\n\n* Estimated Glomerular Filtration Rate (eGFR) less than 60 ml\u002Fmin\u002F1.73 m² and greater than or equal to 15 ml\u002Fmin\u002F1.73 m².\n* Adult patients, age 18 years or older.\n* Diagnosis of Chronic Kidney Disease (CKD).\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients currently undergoing regular hemodialysis.\n* History of kidney transplantation or are kidney transplant recipients.\n* Pregnant females.\n* Patients with a history of coronary artery bypass grafting (CABG).\n* Known allergy or contraindication to pentoxifylline.\n* Inability to comply with study procedures or attend follow-up visits.","ALL","18 Years",{"count":53,"type":54},80,"ESTIMATED","INTERVENTIONAL",[57,58],"PHASE1","PHASE2","This study is research to find out if the drug pentoxifylline can help prevent or lessen the problem of blood vessel hardening (vascular calcification) in people with chronic kidney disease (CKD). People with CKD are at higher risk for heart problems and blood vessel hardening. Vascular calcification happens when calcium builds up in the blood vessels, making them stiff. Pentoxifylline is a drug that might have helpful effects that could reduce this hardening. In this study, some CKD patients will receive pentoxifylline in addition to their usual medications, while others will only receive their usual medications. The researchers will then compare the amount of vascular calcification in both groups over 6 months to see if pentoxifylline makes a difference. The goal is to learn if pentoxifylline could be a new way to protect the blood vessels of people with chronic kidney disease.",[61,62,63],"Chronic Kidney Disease","Vascular Calcification","Kidney Failure, Chronic",[63,62,65,66],"Pentoxifylline","CKD","NOT_YET_RECRUITING","2025-03-25",{"date":70,"type":71},"2025-04-01","ACTUAL",{"date":73,"type":54},"2025-04-15",{"date":75,"type":54},"2025-10-30",{"name":5,"class":6}]